Metabolic Syndrome, Obesity Independently Linked to Breast Cancer
By Elana Gotkine HealthDay Reporter
MONDAY, May 13, 2024 -- Metabolic syndrome (MetS) and obesity have independent and distinct associations with breast cancer subtypes and mortality, according to a study published online May 13 in Cancer.
Rowan T. Chlebowski, M.D., Ph.D., from The Lundquist Institute in Torrance, California, and colleagues examined the associations of MetS and obesity with postmenopausal breast cancer. The study population included 63,330 postmenopausal women without prior breast cancer and with normal mammogram, who had an entry MetS score (0, 1 to 2, 3 to 4), which included high waist circumference, high blood pressure, high-cholesterol history, and diabetes history.
The researchers found that after adjustment for body mass index, a higher MetS score was associated with more poor-prognosis, estrogen receptor (ER)-positive, progesterone receptor (PR)-negative cancers after more than 20 years of follow-up (hazard ratio, 1.47 for 3 to 4 versus 0), with increased breast cancer mortality and more deaths after breast cancer (hazard ratios, 1.44 and 1.53 for score of 3 to 4 versus 0). In analyses adjusted for MetS score, obesity status was associated with more good-prognosis ER-positive, PR-positive cancers and with a higher incidence of breast cancer. There was an increase in deaths seen after breast cancer among overweight and obese women, but breast cancer mortality was only significantly higher in women with grade 2 to 3 obesity.
"Postmenopausal women with higher MetS scores are a previously unrecognized population at higher breast cancer mortality risk," Chlebowski said in a statement.
Several authors disclosed financial ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Donepezil Not Beneficial for Cognitive Impairment in Breast Cancer Survivors
FRIDAY, May 24, 2024 -- A once-daily dose of donepezil does not improve cognitive function among breast cancer survivors exposed to chemotherapy one to five years earlier...
ASCO: Survivors of Early Breast Cancer Can Successfully Attempt Pregnancy
THURSDAY, May 23, 2024 -- Most survivors of stage 0 to III breast cancer who attempt pregnancy postdiagnosis are able to become pregnant and have a live birth, according to a...
4-Dimensional Model Can Predict Lymph Node Metastases in Breast Cancer
THURSDAY, May 23, 2024 -- A deep learning model using tumor dynamic contrast-enhanced breast magnetic resonance imaging (MRI) has high sensitivity for identifying lymph node...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.